Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
A large cardiovascular outcomes trial found that higher proportions of tirzepatide recipients reported vomiting, diarrhea, and nausea compared to those taking a selective GLP-1RA
After 7 months, the offering is generating $100M in run-rate revenue across 100k incremental subscribers
You Are Still in the Dose Adjustment Phase Many patients begin at a low dose that is not intended to fully suppress appetite
& Newman, T
GoodRx on Monday said it will also launch a weight-loss telehealth service for Wegovy and Ozempic at $39 a month for subscribers who sign up before February 1, 2026, rising to $119 a month afterward
Other GLP-1 Receptor Agonists: Alternatives include dulaglutide and liraglutide, offering similar benefits
